Biocept, Inc. is a cancer diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), tests utilizing a standard blood sample. Its marketed tests are OncoCEE-BR for breast cancer CTC enumeration and analysis, OncoCEE-GA for gastric cancer CTC enumeration and analysis and OncoCEE-LU for non-small cell lung cancer, or NSCLC, CTC enumeration and analysis. Its marketed test and the tests under development for the enumeration and analysis of CTCs utilize its Cell Enrichment and Extraction, or CEE, technology, and the tests under development for the detection and analysis of ctDNA utilize the Company's CEE-Selector technology, each performed on a standard blood sample. The CEE technology is an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing real-time biomarker monitoring with a standard blood sample.